Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Down on Analyst Downgrade

Viridian Therapeutics, Inc. (NASDAQ:VRDN) gapped down before the market opened on Monday after The Goldman Sachs Group lowered their price target on the stock from $41.00 to $36.00. The stock had previously closed at $27.39, but opened at $17.00. The Goldman Sachs Group currently has a buy rating on the stock. Viridian Therapeutics shares last traded at $18.1620, with a volume of 4,451,127 shares.

A number of other equities analysts have also commented on VRDN. UBS Group started coverage on shares of Viridian Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target on the stock. Wall Street Zen cut shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Wedbush cut their price objective on Viridian Therapeutics from $44.00 to $37.00 and set an “outperform” rating for the company in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Wednesday, January 21st. Finally, Needham & Company LLC reduced their price objective on Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating for the company in a research report on Monday. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.21.

Key Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 Phase 3 topline: The trial for elegrobart met its primary endpoint (statistically significant proptosis responder rates vs. placebo), confirming efficacy signals for the subcutaneous antibody. This is a fundamental clinical positive for Viridian’s lead program. BusinessWire release
• Neutral Sentiment: HC Wainwright kept a “Buy” rating and set a $22 price target while adjusting its FY2026 and quarterly EPS forecasts modestly (Q1/Q2/Q4 and FY estimates were nudged lower). The firm’s maintained Buy reduces some downside narrative but the lower target reflects more conservative modeling. (HC Wainwright research note)
• Negative Sentiment: Big investor reaction and heavy selling: multiple outlets report a large share decline (over 30% intraday; ~41% pre-market in some reports) despite the positive topline — suggesting the market was either disappointed by aspects of the readout, worried about commercialization prospects, or reacting to revised expectations. MSN coverage
• Negative Sentiment: Analyst price‑target cuts and re-ratings: Several brokers reduced targets or reset views after the data — HC Wainwright cut its target to $22, Wells Fargo to $20 (equal weight), Needham to $32, Wedbush to $37, and Goldman trimmed its target to $36 — increasing near-term downward pressure on the stock. Benzinga roundup
• Negative Sentiment: Follow‑on coverage highlighting the selloff and market confusion: multiple stories (Proactive, Investing.com, Bioworld) note the stock “tumbled despite trial success,” signaling that headlines and investor interpretation of the readout — not just the data itself — are driving volatility. Proactive article

Hedge Funds Weigh In On Viridian Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VRDN. MetLife Investment Management LLC lifted its stake in Viridian Therapeutics by 0.8% during the fourth quarter. MetLife Investment Management LLC now owns 43,985 shares of the company’s stock worth $1,369,000 after purchasing an additional 356 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Viridian Therapeutics by 0.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company’s stock valued at $4,337,000 after purchasing an additional 380 shares during the period. US Bancorp DE raised its holdings in shares of Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after buying an additional 463 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Viridian Therapeutics by 1.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after buying an additional 876 shares in the last quarter. Finally, Virtus Investment Advisers LLC lifted its position in shares of Viridian Therapeutics by 13.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 8,233 shares of the company’s stock worth $256,000 after buying an additional 971 shares during the period.

Viridian Therapeutics Price Performance

The company has a 50-day moving average of $29.16 and a 200 day moving average of $27.89. The company has a debt-to-equity ratio of 0.08, a quick ratio of 12.65 and a current ratio of 12.65. The firm has a market cap of $2.00 billion, a P/E ratio of -5.95 and a beta of 1.00.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The company had revenue of $0.13 million for the quarter, compared to analyst estimates of $15.75 million. On average, sell-side analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.